Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002215 · ClinicalTrials.gov registry record · NA

A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive

A NA study of HIV Infections, sponsored by Triangle Pharmaceuticals.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002215: Completed NA study of HIV Infections, sponsored by Triangle Pharmaceuticals.

NCT00002215 is a NA study of HIV Infections that has completed, run by Triangle Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002215, a NA study of HIV Infections, has completed, sponsored by Triangle Pharmaceuticals.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To compare the proportion of patients whose plasma HIV-1 RNA level falls and remains below the limit of quantification by the Roche Amplicor Monitor (400 copies/ml)\[AS PER AMENDMENT 8/4/98: 50 copies/ml\] between weeks 0 and 24. To determine the short-term safety and tolerability of MKC-442 plus nelfinavir (Viracept) plus dual nucleoside analogs. To determine the time to viral failure and time to tolerability failure through Week 48 of therapy.

Conditions Studied

HIV Infections

Interventions

  • DRUG Nelfinavir mesylate
  • DRUG Emivirine

Study Locations (1)

Pennsylvania

  • Anderson Clinical Research - Pittsburgh

Trial Details

FieldValue
Phase NA
Triangle Pharmaceuticals

3 total trials

What the finished NCT00002215 record still lists

NCT00002215 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Nelfinavir mesylate is the first listed.

NCT00002215 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00002215 about?

NCT00002215 is a clinical study titled "A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive". To compare the proportion of patients whose plasma HIV-1 RNA level falls and remains below the limit of quantification by the Roche Amplicor Monitor (400 copies/ml)\[AS PER AMENDMENT 8/4/98: 50 copies/ml\] between weeks 0 and 24. To determine the short-term safety and tolerability of MKC-442 plus ne...

What is the current status of trial NCT00002215?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002215 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002215?

The interventions under investigation include: Nelfinavir mesylate (DRUG), Emivirine (DRUG).

Who is sponsoring clinical trial NCT00002215?

This trial is sponsored by Triangle Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002215 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002215, the US trial registry maintained by the National Library of Medicine. NCT00002215 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.